Trials
1 active
6 in total
What this is
- How it works
- Retinoid FDA class
- Tested for
- Acne Vulgaris
- Main trialPhase 3
- “The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.”In the company’s words, NCT07186413 on ClinicalTrials.gov
- Other names
- CD5789 · AKLIEF
Other drugs for Acne Vulgaris
- Cyproterone Acetate and Ethinyl EstradiolEurofarma Laboratorios S.A. · Phase 3
- DenifanstatSagimet Biosciences Inc. · Ascletis · Phase 3
- ClascoteroneZhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Phase 3
- B244AOBiome LLC · Phase 2
- Acne mRNA vaccineSanofi · Phase 1/2
- HB0043Huahai Pharmaceutical (Huaota) · Phase 1/2
Copies tested against it2
Other companies’ versions, mostly cheaper copies for when the patent ends
- Trifarotene Cream 0.005%Sun Pharmaceutical Industries, Inc. · NCT06733402, NCT06063473 · finished
- Trifarotene 0.005 % Topical CreamTeva Pharmaceuticals USA · NCT05550337 · finished
Coming up1
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2026 | A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | |
| Phase 4Completed | 26 Apr 2021 | A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) | |
| Phase 4Completed | 15 Dec 2022 | AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation | |
| Phase 4Completed | 8 Feb 2023 | Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation | |
| Phase 3Completed | 23 Dec 2019 | Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris | |
| Phase 2Completed | 24 Jul 2013 | Dose Range Study of CD5789 in Acne Vulgaris |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026